Magee Thomson Investment Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Magee Thomson Investment Partners’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-260	Closed	-$1K	–	117
2015 Q4	$1K	Hold	260	–	–	﹤0.01%	99
2015 Q3	$2K	Hold	260	–	–	﹤0.01%	102
2015 Q2	$4K	Hold	260	–	–	﹤0.01%	99
2015 Q1	$4K	Hold	260	–	–	﹤0.01%	95
2014 Q4	$4K	Hold	260	–	–	﹤0.01%	150
2014 Q3	$4K	Sell	260 -35	-12%	-$431	﹤0.01%	138
2014 Q2	$4K	Sell	295 -2	-0.7%	-$31	﹤0.01%	145
2014 Q1	$6K	Hold	297	–	–	﹤0.01%	136
2013 Q4	$6K	Buy	+297	New	+$7.92K	﹤0.01%	130

Other funds holding STML

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Magee Thomson Investment Partners's STML Position: Q1 2016 in Review

Magee Thomson Investment Partners sold out of Stemline Therapeutics, Inc. (STML) in Q1 2016, closing a stake of 260 shares — an estimated $1K sold.

Magee Thomson Investment Partners first reported a position in STML in Q4 2013 and held it in 9 quarters. The position peaked at $6K in Q1 2014. 63 funds tracked by Wall St. Rank hold STML as of Q1 2016.

Magee Thomson Investment Partners reported no remaining Stemline Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Magee Thomson Investment Partners sold 260 Stemline Therapeutics, Inc. shares in Q1 2016, an estimated $1K.
Magee Thomson Investment Partners first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 9 quarters.
Magee Thomson Investment Partners's Stemline Therapeutics, Inc. position peaked at $6K in Q1 2014.
63 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2016, filed 20 Apr 2016.